Ohio State investigators reported early clinical signals from a phase I study using fresh, rapidly manufactured CAR T cells engineered to target three B-cell proteins and boosted with OX40. In relapsed B-cell blood cancers, the approach produced remissions with minimal side effects, while the manufacturing timeline was compressed to about six days. The study’s emphasis on speed and a multi-target antigen strategy addresses two persistent CAR T constraints: time-to-treatment and antigen escape. By using a three-antigen design, the platform aims to broaden coverage across heterogeneous B-cell malignancies. For clinicians and developers, the key datapoint is the combination of clinical activity and a tolerability profile in an early-stage trial, alongside a workflow that could reduce barriers to delivery. The report provides a platform-level update rather than randomized comparisons, but it strengthens momentum behind next-generation CAR constructs that attempt to improve practicality without sacrificing potency.